​

ArriVent BioPharma (AVBP) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

AVBP Stock Forecast

ArriVent BioPharma (AVBP) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $35.67, with a high of $36.00 and a low of $35.00. This represents a 50.95% increase from the last price of $23.63.

$15 $20 $25 $30 $35 $40 High: $36 Avg: $35.67 Low: $35 Last Closed Price: $23.63

AVBP Stock Rating

ArriVent BioPharma stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

AVBP Price Target Upside V Benchmarks

TypeNameUpside
StockArriVent BioPharma50.95%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$34.25
Last Closing Price$23.63$23.63$23.63
Upside/Downside--44.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2517---8
May, 2516---7
Apr, 2516---7
Mar, 2514---5
Feb, 2514---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2024Yigal NochomovitzCitigroup$36.00$27.9328.89%52.35%
Sep 10, 2024Robert BurnsH.C. Wainwright$36.00$28.0428.39%52.35%
Aug 16, 2024Robert BurnsH.C. Wainwright$30.00$23.6227.01%26.96%
Jul 22, 2024Jeff JonesOppenheimer$35.00$18.7786.47%48.12%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2024CitigroupBuyBuyhold
Sep 10, 2024OppenheimerOutperformOutperformhold
Sep 10, 2024H.C. WainwrightBuyBuyhold
Aug 16, 2024H.C. WainwrightBuyBuyhold
Jul 22, 2024OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-2.07----
Avg Forecast$-8.54$-2.70$-3.25$-3.70$-2.41
High Forecast$-8.54$-2.63$-2.27$-2.13$-2.41
Low Forecast$-8.54$-2.86$-3.82$-4.57$-2.41
Surprise %-75.76%----

Revenue Forecast

$-5M $12M $29M $46M $63M $80M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$-1.67M$3.00M$5.50M$4.85M$76.63M
High Forecast$-1.67M$3.00M$5.50M$4.85M$78.89M
Low Forecast$-1.67M$3.00M$5.50M$4.85M$74.37M
Surprise %-----

Net Income Forecast

$-300M $-250M $-200M $-150M $-100M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-69.33M----
Avg Forecast$-272.93M$-87.65M$-106.52M$-114.65M$-77.02M
High Forecast$-272.93M$-84.03M$-72.62M$-67.91M$-77.02M
Low Forecast$-272.93M$-91.27M$-122.10M$-146.04M$-77.02M
Surprise %-74.60%----

AVBP Forecast FAQ

Is ArriVent BioPharma stock a buy?

ArriVent BioPharma stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ArriVent BioPharma is a favorable investment for most analysts.

What is ArriVent BioPharma's price target?

ArriVent BioPharma's price target, set by 4 Wall Street analysts, averages $35.67 over the next 12 months. The price target range spans from $35 at the low end to $36 at the high end, suggesting a potential 50.95% change from the previous closing price of $23.63.

How does ArriVent BioPharma stock forecast compare to its benchmarks?

ArriVent BioPharma's stock forecast shows a 50.95% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for ArriVent BioPharma over the past three months?

  • June 2025: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ArriVent BioPharma’s EPS forecast?

ArriVent BioPharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.7, marking a 30.43% increase from the reported $-2.07 in 2023. Estimates for the following years are $-3.25 in 2025, $-3.7 in 2026, and $-2.41 in 2027.

What is ArriVent BioPharma’s revenue forecast?

ArriVent BioPharma's average annual revenue forecast for its fiscal year ending in December 2024 is $3M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $5.5M, followed by $4.85M for 2026, and $76.63M for 2027.

What is ArriVent BioPharma’s net income forecast?

ArriVent BioPharma's net income forecast for the fiscal year ending in December 2024 stands at $-87.647M, representing an 26.42% increase from the reported $-69.333M in 2023. Projections indicate $-107M in 2025, $-115M in 2026, and $-77.016M in 2027.